- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02508376
Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects
A Phase 1, Randomized, Double Blind Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242-2600
- University of Iowa - Vaccine Research and Education Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Males and nonpregnant females between the ages of 18 and 49 years, inclusive. 2. Women of childbearing potential* must agree to practice adequate contraception** for the 28-day period before Day 0 through 90 days after the third study injection. * A woman is considered of childbearing potential unless surgically sterile (tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal (>/=1 year). **Acceptable birth control methods include but are not limited to: abstinence from sexual intercourse with men; monogamous relationship with a vasectomized partner; barrier methods (condoms, diaphragms, spermicides, and intrauterine devices); and licensed hormonal methods. 3. In good health, as judged by the investigator and determined by vital signs*, medical history, and a targeted physical examination. * Temperature <38°C, heart rate </=100 bpm and >54 bpm, systolic blood pressure </=140 mmHg and >89 mmHg, diastolic blood pressure </=90 mmHg and >/=60 mmHg. NOTE: Athletically trained subjects with a pulse >/=45 may be enrolled at the discretion of the principal investigator or designated licensed clinical investigator. 4. Screening laboratory values must be within site normal limits, though trace urine protein is acceptable. -Blood hemoglobin -White blood cell (WBC) count -Neutrophil count -Platelets -Creatinine -AST -ALT -Bilirubin (total) -Glucose (random, must be less than 140) -Urine dipstick for protein and glucose (negative to trace protein are acceptable) -Negative Quantiferon-TB Gold test -Negative HIV 1/2 antibody, (HBsAg), and Hepatitis C virus (HCV) antibody NOTE: See Appendix D for site normal values. Creatinine values lower than the normal range may be acceptable if the PI or a designated licensed clinician determines that these laboratory findings are not clinically significant. HIV and hepatitis C viral load PCR testing may be performed for individuals suspected of having indeterminate antibody testing. For African American participants, a WBC of >/= 3.5 k/mm^3 is acceptable. 5. Able to understand and comply with planned study procedures and willing to be available for all study-required procedures, visits and calls for the duration of the study. 6. Provide written informed consent before initiation of any study procedures. 7. Willing to abstain from donating whole blood or blood derivatives until 90 days after the final study injection.
Exclusion Criteria:
1. History of treatment for active or latent tuberculosis infection or history of positive PPD. 2. History or evidence of active tuberculosis. 3. Has received vaccination or immunotherapy with a BCG product at any time prior to randomization. 4. Shared a residence within the last year prior to randomization with an individual on anti-tuberculosis treatment or with culture or smear positive tuberculosis. 5. Received a tuberculin skin test within 3 months (90 days) prior to the time of randomization through study day 85. 6. Body temperature >/=100.4°F (>/=38°C) or acute illness within 3 days before study injection days (subject may be rescheduled). 7. A positive serum* or urine pregnancy test at screening or within 24 hours prior to study injection**, women who are planning to become pregnant***, or women who are breastfeeding. * At screening visit only ** If female of childbearing potential as defined in Inclusion Criterion #2 ***from 28 days prior to entering the study until 90 days after the final study injection 8. Immunosuppression as a result of an underlying illness or treatment or use of anticancer chemotherapy or radiation therapy (cytotoxic) within the preceding 36 months. 9. An active neoplastic disease* (excluding nonmelanoma skin cancer) or a history of any hematologic malignancy. * defined as neoplastic disease or treatment for neoplastic disease within the past 5 years 10. A history of autoimmune disease (systemic lupus, rheumatoid arthritis, scleroderma, polyarteritis, thyroiditis, etc). 11. Used an immunosuppressive or immunomodulatory drug* for 2 or more consecutive weeks within 6 months prior to the first study injection (nasal and topical steroids are allowed). *such as >0.5 mg/kg/day or >/=20 mg total dose/day of prednisone orally or >800 µg of inhaled beclomethasone 12. A diagnosis of schizophrenia, bipolar disease, or history of hospitalization for a psychiatric condition or previous suicide attempt. 13. A history of treatment for any other psychiatric disorder in the past 3 years that increases the risk to the subject in the opinion of the investigator. 14. A history of receiving immunoglobulin or other blood product within 3 months prior to enrollment through study day 85. 15. Received or plan to receive any live licensed vaccines within 4 weeks or inactivated licensed vaccines within 2 weeks of any study injection. 16. An acute or chronic medical condition that* would render study injections unsafe or would interfere with the evaluation of responses or is not generally seen in healthy, normal subjects. * in the opinion of the investigator NOTE: This includes, but is not limited to, known cardiac disease, pulmonary disease, liver disease, renal disease, unstable or progressive neurological disorders, diabetes mellitus, and transplant recipients. 17. History of anaphylaxis or severe allergic reaction to vaccines or history of allergic reaction to eggs, kanamycin-related antibiotics or other components in the antigen and adjuvant formulations. 18. Receipt of an experimental agent* within 1 month before study injections in this study or expectation to receive an experimental agent during the 15-month study period. * vaccine, drug, biologic, device, blood product, or medication 19. Any condition that would* place the subject at an unacceptable injury risk, render him/her unable to meet the requirements of the protocol, or that may interfere with successful study completion. * in the opinion of the investigator 20. A history of alcohol or drug abuse during the previous 1 year* or chronic marijuana abuse or any other illicit drug use. * for example, daily excessive alcohol use or frequ ent binge drinking as determined by the investigator 21. Presence of tattoos that would preclude evaluation of the injection site.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ID93 (10 mcg) + AP10-602 (10 mcg)
N=20 subjects will receive intervention on Days 1, 29, 57
|
AP10-602 contains GLA formulated with liposomes and an additional immunological adjuvant.
The ID93 (10 mcg) + AP10-602 (5 mcg) arm will receive intervention on days 1, 29 and 57.
The ID93 (10 mcg) + AP10-602 (10 mcg) arm will receive intervention on days 1, 29 and 57.
ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813).
All arms will receive 10 mcg ID93 IM on days 1, 29 and 57
|
Experimental: ID93 (10 mcg) + AP10-602 (5 mcg)
N=20 subjects will receive intervention on Days 1, 29, 57
|
AP10-602 contains GLA formulated with liposomes and an additional immunological adjuvant.
The ID93 (10 mcg) + AP10-602 (5 mcg) arm will receive intervention on days 1, 29 and 57.
The ID93 (10 mcg) + AP10-602 (10 mcg) arm will receive intervention on days 1, 29 and 57.
ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813).
All arms will receive 10 mcg ID93 IM on days 1, 29 and 57
|
Experimental: ID93 (10 mcg) + GLA-SE (5 mcg)
N=20 subjects will receive intervention on Days 1, 29, 57
|
ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813).
All arms will receive 10 mcg ID93 IM on days 1, 29 and 57
Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE).
The ID93 (10 mcg) + GLA-SE (5 mcg) arm will receive intervention on days 1, 29 and 57
|
Experimental: ID93 (10 mcg) alone
N=10 subjects will receive intervention on Days 1, 29, 57
|
ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813).
All arms will receive 10 mcg ID93 IM on days 1, 29 and 57
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number of serious adverse events considered related to the study injection reported at any point during the study period.
Time Frame: Day 1 through Day 422
|
Day 1 through Day 422
|
The number of subjects experiencing solicited injection site reactions within 7 days following study injection.
Time Frame: 7 days following each study injection
|
7 days following each study injection
|
The number of subjects experiencing solicited systemic reactions within 7 days following study injection.
Time Frame: 7 days following each study injection
|
7 days following each study injection
|
The number of subjects spontaneously reporting adverse events considered related to the study injection at any point during the study period.
Time Frame: Day 1 through Day 422
|
Day 1 through Day 422
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean fold change from baseline (Day 1) in IgG antibody responses to ID93 on Day 85.
Time Frame: Day 1 and Day 85
|
Day 1 and Day 85
|
Percentage of CD4 and CD8 T cells producing 1 or more cytokines (IFN-gamma, TNF and IL-2) simultaneously in response to stimulation with the ID93 antigen as measured by intracellular cytokine staining at Day 71 relative to baseline (Day 1).
Time Frame: Day 1 and Day 71
|
Day 1 and Day 71
|
The magnitude of Th1 and Th2 cytokine production in PBMCs in response to the ID93 antigen relative to baseline (Day 1) at Day 71, as assayed by Luminex.
Time Frame: Day 1 and Day 71
|
Day 1 and Day 71
|
The proportion of subjects with at least a 4-fold increase in IgG antibody responses to ID93 on Day 85 relative to baseline (Day 1).
Time Frame: Day 1 through Day 85
|
Day 1 through Day 85
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-0109
- HHSN272201300020I
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...CompletedPulmonary Tuberculosis | Multidrug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisKorea, Republic of
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsActive, not recruitingTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
Clinical Trials on AP10-602
-
National Institute of Allergy and Infectious Diseases...Completed
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); ADC Therapeutics S.A.RecruitingRecurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | CD22 PositiveUnited States
-
C.B. Fleet Company, Inc.CompletedBowel Cleansing Prior to ColonoscopyUnited States
-
Med-El CorporationRecruitingHearing Loss, Conductive | Hearing Loss, MixedUnited States
-
Palleon Pharmaceuticals, Inc.RecruitingMelanoma | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer | Bladder Cancer | Colon Cancer | Urothelial Cancer | Oncology | CRC | Esophagogastric Junction Cancer | EGJUnited States
-
Sokbom KangCompletedCervical CancerKorea, Republic of